This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

BELLUS Health Dividende

Dividende contrôle des critères 0/6

BELLUS Health does not have a record of paying a dividend.

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	1.9%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	-CA$0.68
Prévision de rendement du dividende	n/a

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Jan 16

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

Sep 07

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Insufficient data to determine if BLU's dividends per share have been stable in the past.

Dividende croissant: Insufficient data to determine if BLU's dividend payments have been increasing.

Rendement des dividendes par rapport au marché

BELLUS Health Rendement des dividendes par rapport au marché

Comment le rendement du dividende de BLU se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (BLU)	n/a
25% du marché (CA)	1.8%
25% du marché (CA)	6.0%
Moyenne du secteur (Biotechs)	1.9%
Analyste prévisionnel (BLU) (jusqu'à 3 ans)	n/a

Dividende notable: Unable to evaluate BLU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividende élevé: Unable to evaluate BLU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Bénéfice distribué aux actionnaires

Couverture des revenus: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as BLU has not reported any payouts.

This company has been acquired

BELLUS Health Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

BELLUS Health Inc.(NasdaqGS:BLU) dropped from NASDAQ Composite Index

GSK plc (LSE:GSK) completed the acquisition of BELLUS Health Inc. (TSX:BLU).

President exercised options to buy CA$35m worth of stock.

Consensus revenue estimates increase by 40%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates decrease by 22%, EPS upgraded

Price target decreased by 30% to CA$14.75

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Insufficient new directors

Independent Lead Director recently sold CA$449k worth of stock

President exercised options and sold CA$3.1m worth of stock

Independent Director recently sold CA$433k worth of stock

Consensus revenue estimates fall by 93%

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

First half 2022 earnings released

BELLUS Health Inc. Expects to Initiate A Phase 1 Clinical Trial Investigating A Once-Daily, Extended-Release Formulation of BLU-5937 in the Fourth Quarter of 2022

Bellus Health Inc. Announces Positive End-Of-Phase 2 Meeting with the FDA and Its Calm Phase 3 Program for BLU-5937 in Refractory Chronic Cough

Price target increased to CA$18.50

Consensus revenue estimates increase by 56%

We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely

Senior Vice President of Finance recently sold CA$576k worth of stock

Chief Scientific Officer recently sold CA$951k worth of stock

BELLUS Health Inc., Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Consensus forecasts updated

Consensus revenue estimates increase by 16%

Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation

Bellus Health Announces Positive Topline Results from Its Phase 2B Soothe Trial of Blu-5937 for the Treatment of Refractory Chronic Cough

Price target increased to CA$16.40

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.094 loss in 3Q 2020)

BELLUS Health Inc. Announces Completion of Patient Enrollment in Soothe Phase 2B Trial for Refractory Chronic Cough and Blueprint Phase 2A Trial for Chronic Pruritus Associated with Atopic Dermatitisz

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

Price target increased to CA$10.70

Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés